Which anti‑tuberculosis drugs are nephrotoxic and how should they be dosed or substituted in patients with impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nephrotoxic Anti-TB Drugs and Management in Renal Impairment

Primary Nephrotoxic Agents

The injectable second-line anti-TB drugs—aminoglycosides (amikacin, kanamycin, streptomycin) and capreomycin—are the most nephrotoxic anti-TB medications and require dose frequency reduction to 2-3 times weekly in patients with creatinine clearance <30 mL/min 1.

These injectable agents cause dose-related nephrotoxicity with prevalence ranging from 10-18% during intensive phase treatment 2. The nephrotoxicity manifests through various mechanisms including acute interstitial nephritis, crescentic glomerulonephritis, and acute tubular necrosis 3.

Other Nephrotoxic/Renally-Cleared Drugs

Ethambutol and Pyrazinamide

  • Ethambutol is approximately 80% renally cleared and accumulates in renal insufficiency 1
  • Pyrazinamide metabolites (pyrazinoic acid and 5-hydroxy-pyrazinoic acid) accumulate despite hepatic metabolism 1
  • Both require frequency reduction to 3 times weekly (not daily) at doses of 20-25 mg/kg for ethambutol and 25-35 mg/kg for pyrazinamide when creatinine clearance <30 mL/min 1

Fluoroquinolones

  • Levofloxacin undergoes significant renal clearance and requires frequency reduction to 3 times weekly (750-1000 mg/dose) 1
  • Moxifloxacin has minimal renal clearance and requires no dose adjustment (400 mg daily) 1

Cycloserine

  • Requires reduction to 250 mg once daily or 500 mg 3 times weekly 1
  • Start with 250 mg daily and verify with therapeutic drug monitoring in renal disease 4

Non-Nephrotoxic Drugs (No Adjustment Needed)

Rifampin and isoniazid are hepatically metabolized and require no dose adjustment in renal insufficiency 1. Standard dosing: rifampin 600 mg daily/3 times weekly, isoniazid 300 mg daily/900 mg 3 times weekly.

Newer agents with no adjustment needed:

  • Bedaquiline: No change needed 4
  • Moxifloxacin: No change needed 4, 1
  • Ethionamide: 250-500 mg daily 1
  • Para-aminosalicylic acid: 4 g twice daily 1

Critical Dosing Principles

Interval Extension vs. Dose Reduction

Increase the interval between doses rather than reducing individual doses to maintain peak serum concentrations and treatment efficacy 1. Decreasing doses lowers peak concentrations and compromises efficacy.

Hemodialysis Considerations

  • Administer all anti-TB drugs after hemodialysis to facilitate directly observed therapy and prevent premature drug clearance 1
  • Pyrazinamide and its metabolites are significantly cleared by hemodialysis 1
  • Isoniazid and ethambutol are partially cleared 1
  • Rifampin is not cleared by hemodialysis 1

Therapeutic Drug Monitoring

Monitor serum drug concentrations (2 and 6 hours post-dose) in patients with creatinine clearance 30-50 mL/min to optimize dosing 1. This is essential in end-stage renal disease patients who often have drug interactions and comorbidities 1.

Clinical Monitoring Requirements

Patients with CKD experience more frequent (48.0% vs 13.7%) and more severe adverse drug reactions compared to those with normal renal function, despite dose adjustments 5. The most common adverse effects include:

  • Hepatobiliary toxicity (30.6% vs 8.9%)
  • Neuropsychiatric effects (10.6% vs 1.2%)
  • Renal toxicity (5.3% vs 0.4%)
  • Gastrointestinal effects (6.6% vs 1.9%) 5

Monitor baseline and monthly serum creatinine throughout intensive phase treatment 2. Severe CKD stage is an independent risk factor for regimen change (OR=5.92) 6.

Common Pitfalls

  • Avoid reducing individual drug doses—extend dosing intervals instead
  • Do not assume hepatically-metabolized drugs (pyrazinamide) are safe—metabolites accumulate
  • Remember that rifampin can cause acute kidney injury through immune-mediated mechanisms (interstitial nephritis, crescentic glomerulonephritis) even though it doesn't require dose adjustment 3
  • In borderline renal function, obtain 24-hour urine collection for accurate creatinine clearance before making regimen changes 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.